SRPT

Sarepta Therapeutics Inc

17.25

Jun 29 • 03:38PM ET +0.40 (2.37%)

Healthcare Biotechnology USA Small NASD

Peers: BMRN RARE PTCT MIRM RYTM KRYS IONS ALNY INCY NTLA

| Held by: IJR XBI FBT VTI IWM VB VBK VXF SPSM IWN

Scroll to Statements

Index	-
Market Cap	1.82B
Enterprise Value	2.20B
Income	-64.32M
Sales	2.18B
Book/sh	14.26
Cash/sh	6.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	835
IPO	Jun 04, 1997

P/E	-
Forward P/E	17.30
PEG	-
P/S	0.83
P/B	1.21
P/C	2.79
P/FCF	18.62
EV/EBITDA	34.35
EV/Sales	1.01
Quick Ratio	2.62
Current Ratio	4.63
Debt/Eq	0.69
LT Debt/Eq	0.69
Option/Short	Yes / Yes

EPS (ttm)	-0.96
EPS next Y	1.00
EPS next Q	0.21
EPS this Y	149.59%
EPS next Y	-71.80%
EPS next 5Y	-
EPS past 3/5Y	3.92% -0.05%
Sales past 3/5Y	33.06% 32.41%
EPS Y/Y TTM	77.51%
Sales Y/Y TTM	-2.20%
EPS Q/Q	162.61%
Sales Q/Q	-1.89%
Earnings	May 06 AMC
EPS/Sales Surpr.	195.11% 54.13%

Insider Own	4.41%
Insider Trans	-0.16%
Inst Own	101.17%
Inst Trans	11.44%
ROA	-1.94%
ROE	-4.86%
ROIC	-2.53%
Gross Margin	60.59%
Oper. Margin	0.05%
Profit Margin	-2.94%
SMA20	5.46%
SMA50	-5.38%
SMA200	-12.38%
Trades

Shs Outstand	105.57M
Shs Float	100.92M
Short Float	24.94%
Short Ratio	8.04
Short Interest	25.17M
52W High	25.32 -31.87%
52W Low	10.41 65.62%
Volatility	4.89% 5.04%
ATR (14)	0.90
RSI (14)	51.98
Beta	0.22
Rel Volume	0.91
Avg Volume	3.13M
Volume	2,702,299

Perf Week	-2.27%
Perf Month	-0.29%
Perf Quarter	-13.62%
Perf Half Y	-22.72%
Perf YTD	-19.84%
Perf Year	0.82%
Perf 3Y	-84.63%
Perf 5Y	-78.12%
Perf 10Y	-7.56%
Recom	2.74
Target Price	22.67
Prev Close	16.85
Price	17.25
Change	2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Equal Weight	$20
Dec-09-25	Initiated	Wedbush	Outperform	$32
Nov-05-25	Upgrade	Mizuho	Neutral → Outperform	$26
Sep-22-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform	$37
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral	$24
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight	$22
Jul-29-25	Reiterated	H.C. Wainwright	Sell	$5
Jul-29-25	Initiated	Bernstein	Mkt Perform	$13
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight	$10
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell	$7
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight	$18
Jul-21-25	Downgrade	UBS	Buy → Neutral	$12
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral	$14
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform	$10
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold	$9
Jul-18-25	Downgrade	Needham	Buy → Hold

Show Previous Ratings

Jun-08-26 03:00AM	BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors (TMX Newsfile)
Jun-01-26 04:30PM	Sarepta Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) -7.72%
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
May-13-26 04:30PM	Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-07-26 11:51AM	Sarepta tumbles as its gene therapy sales decline further (BioPharma Dive) -9.68%
10:03AM	Loading…
10:03AM	Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy? (Investor's Business Daily)
08:59AM	Sarepta Stock Slumps. Why an Earnings Beat Wasn't Enough for the S&P 500 Loser. (Barrons.com)
May-06-26 08:36PM	Sarepta Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby) +5.69%
06:50PM	Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. (Barrons.com)
04:26PM	Sarepta Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:05PM	Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments (Business Wire)
Apr-22-26 08:30AM	Sarepta Therapeutics to Announce First Quarter 2026 Financial Results (Business Wire)
Apr-16-26 05:58AM	Roche to start new Elevidys study following setback in Europe (BioPharma Dive)
Mar-31-26 04:05PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.25%
Mar-25-26 12:17PM	Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. (Barrons.com) +34.98%
11:37AM	Loading…
11:37AM	Sarepta Therapeutics experimental siRNA therapies show promising early results (Proactive)
10:05AM	Sarepta Surges As It Takes On Novartis' $12 Billion Muscular Dystrophy Buyout (Investor's Business Daily)
08:05AM	Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 (Business Wire)
07:03AM	Sarepta sees early success with RNAi drugs from Arrowhead (BioPharma Dive)
Mar-24-26 04:05PM	Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 (Business Wire)
Mar-23-26 06:16AM	FDA seeks feedback on voucher program; Study data lift overhang on Insmed shares (BioPharma Dive) +6.11%
Mar-19-26 08:30AM	Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53 (Business Wire)
Mar-16-26 08:33AM	Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne (Business Wire)
05:06AM	Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy (BioPharma Dive)
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +5.57%
07:59AM	UniQure leads genetic medicine biotech rally after news of Prasads exit (BioPharma Dive)
07:01AM	Why Is uniQure Stock Skyrocketing Monday? (Benzinga)
Mar-06-26 05:56PM	FDA vaccine chief Vinay Prasad set to leave post next month (Bloomberg)
11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
03:00AM	Biopharmas recent string of CEO splits (Pharma Voice)
04:27AM	Loading…
Mar-01-26 04:27AM	Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45 (Insider Monkey)
Feb-28-26 11:58AM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
09:30AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
Feb-27-26 09:00AM	Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
Feb-26-26 10:29AM	Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates (Zacks) -8.01%
09:30AM	Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics (Zacks)
08:30AM	Sarepta Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
08:30AM	Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress (Business Wire)
05:52AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
03:08AM	Sarepta Therapeutics Q4 Earnings Call Highlights (MarketBeat)
03:00AM	Sarepta CEO Doug Ingram to retire, with company at a crossroads (BioPharma Dive)
12:05AM	Sarepta Therapeutics Inc (SRPT) Q4 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
Feb-25-26 04:40PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments (Business Wire)
Feb-24-26 09:07AM	Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan (Business Wire)
08:30AM	Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-19-26 10:00AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-18-26 10:00AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-15-26 05:35AM	Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreichs Ataxia Update (MarketBeat)
Feb-11-26 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com) +8.63%
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -13.68%
Jan-31-26 12:02AM	Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags (MarketBeat)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
06:45AM	Sarepta eyes Elevidys sales comeback with positive Phase III data (Clinical Trials Arena)
Jan-26-26 04:17PM	Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy? (Investor's Business Daily) +7.90%
02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
12:00PM	Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:56AM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
11:36AM	These Stocks Are Todays Movers: USA Rare Earth, CoreWeave, Micron, Intel, Newmont, IonQ, Sarepta, and More (Barrons.com)
11:23AM	Sarepta Stock Climbs 11% on Positive Three-Year Study Results for Elevidys (Barrons.com)
09:26AM	Sarepta Says Elevidys Slows Duchenne Progression After Three Years (Benzinga)
09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
08:53AM	Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys (Barrons.com)
08:00AM	Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients (Business Wire)
06:46AM	Sarepta, battling slowing sales, claims Duchenne gene therapys impact grows with time (BioPharma Dive)
05:36AM	Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings-Brand Engagement, Nucor In Focus (Benzinga)
Jan-23-26 04:05PM	Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy (Business Wire)
Jan-21-26 10:50PM	2 Beaten-Down Stocks That Could Sink Even More in 2026 (Motley Fool)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks) -6.54%
Jan-13-26 08:08AM	JPM26: Sarepta CEO touts avalanche of Elevidys data amid 2025 safety woes (Pharmaceutical Technology)
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily) -11.29%
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
11:58AM	Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues (Business Wire)
Jan-05-26 08:30AM	Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-25 05:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-25 01:13PM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
Dec-11-25 07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
Dec-03-25 11:30AM	Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report? (Zacks) +6.69%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-25-25 02:17PM	Trump Media Stock and 11 More Tax-Loss Victims to Avoid Until 2026 (Barrons.com)
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
12:07PM	Trump Media and 11 More Stocks to Avoid Until 2026 (Barrons.com)
08:57AM	Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne (Business Wire)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +6.90%
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks) -6.75%
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 03:14PM	FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths (Associated Press Finance) +5.56%
02:54PM	Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information (Business Wire)
Nov-06-25 05:43AM	Sarepta (SRPT) Soars 15% on Bullish Rating (Insider Monkey) -5.52%
Nov-05-25 10:21AM	Mizuho upgrades Sarepta on confidence in Elevidys uptake (Investing.com) +15.25%
03:31AM	Sarepta Stock Tumbles 34% After Earnings Report. Why Shares Crashed. (Barrons.com)
Nov-04-25 04:51PM	These Stocks Moved the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com) -33.74%
04:14PM	Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook (Investor's Business Daily)
02:39PM	These Stocks Are Moving the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com)
01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
11:54AM	Top Stock Movers Now: Palantir, Sarepta Therapeutics, Denny's, and More (Investopedia)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

J.D.Mr. Douglas S. Ingram Esq.

President & COOMr. Ian Michael Estepan

Executive VP & CFOMr. Ryan H. Wong

Executive VPMs. Cristin L. Rothfuss J.D.

President of Research & Development and Technical OperationsDr. Louise R. Rodino-Klapac Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mayo Stephen	Director	Mar 12 '26	Sale	17.02	7,239	123,208	1,765	Mar 13 08:03 PM
STEPHEN MAYO	Director	Mar 12 '26	Proposed Sale	17.02	7,239	123,175		Mar 12 04:27 PM
Estepan Ian Michael	Chief Operating Officer	Feb 26 '26	Option Exercise	13.71	7,450	102,140	200,750	Mar 02 08:00 AM
Nicaise Claude	Director	Jan 29 '26	Option Exercise	13.71	10,500	143,955	38,312	Jan 29 08:05 PM
BEHRENS M KATHLEEN	Director	Jan 27 '26	Option Exercise	13.71	10,500	143,955	203,976	Jan 29 08:04 PM
Estepan Ian Michael	Chief Operating Officer	Dec 16 '25	Sale	22.31	13,187	294,202	193,300	Dec 18 08:05 PM
IAN M ESTEPAN	Officer	Dec 16 '25	Proposed Sale	22.31	13,187	294,145		Dec 16 05:05 PM
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

SRPT

Sarepta Therapeutics Inc

Upgrade your Finviz experience